A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of JTE-051 Administered for 12 Weeks in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR-PS)
Latest Information Update: 09 Aug 2021
At a glance
- Drugs JTE 051 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms CLEAR-PS
- Sponsors Akros Pharma
- 12 Dec 2018 Status changed from recruiting to discontinued.
- 04 Dec 2017 New trial record